Cancer prevention research (Philadelphia, Pa.)最新文献

{"title":"Feasibility and acceptability of pay-it-forward in increasing uptake of HPV vaccination among 15-18-year-old girls in China: Pilot RCT Results.","authors":"Yifan Li, Chuanyu Qin, Katherine T Li, Yu He, Shengyue Qiu, Dan Wu, Jing Li","doi":"10.1158/1940-6207.CAPR-24-0549","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-24-0549","url":null,"abstract":"<p><p>China has low human papillomavirus (HPV) vaccination rate due to limited public funding and mistrust in domestic vaccines. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary effectiveness of an innovative pay-it-forward strategy to improve HPV vaccine uptake among adolescent girls. Conducted at a community health center in Western China (Jan 4 - Feb 18, 2022), the study recruited 100 adolescent girls (ages 15-18) with no prior HPV vaccination. Participants were randomly assigned to either the standard-of-care arm (self-paid vaccines, n=50) or the pay-it-forward arm (subsidized vaccines, hand-written postcards, and the opportunity to donate and/or write postcards, n=50). Feasibility was assessed through recruitment, retention, and questionnaire completion rates. Acceptability and feasibility were measured using the standard scale. Preliminary effectiveness was evaluated by first-dose vaccination rate. Of 109 screened participants, 100 were eligible to participate (91.7%). Retention rate was 100% in both arms. Questionnaire completion rate was 98% (49/50) in the pay-it-forward arm and 82% (41/50) in the standard-of-care arm. Most participants self-reported that the strategy was feasible (97.6%, 41/42) and acceptable (90.5%, 38/42). Ninety seven percent (97/100) of participants made vaccination appointments. The first-dose HPV vaccine uptake rate was 98% (49/50) in the pay-it-forward arm and 82% (41/50) in the standard-of-care arm (P<0.05). No serious adverse events were identified. The pay-it-forward strategy was feasibility, acceptability, and showed preliminary effectiveness in increasing HPV vaccination uptake. Further refinement and population-based recruitment are needed to better reflect local contexts and enhance the generalizability of the formal trial.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution Following Multi-Cancer Early Detection Testing in the PATHFINDER Study.","authors":"Catherine R Marinac, Charles H McDonnell, Lincoln D Nadauld, Christina A Dilaveri, Robert Reid, Karen C Chung, Margarita Lopatin, Eric T Fung, Deborah Schrag, Rita Shaknovich, Eric A Klein","doi":"10.1158/1940-6207.CAPR-24-0468","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-24-0468","url":null,"abstract":"<p><p>Blood-based multi-cancer early detection (MCED) tests represent a new approach for cancer detection. To gain insight into the utility of various approaches of evaluating a cancer signal detected (CSD) test result, we evaluated diagnostic journeys of a subset of 6,662 participants in PATHFINDER who had a CSD on both an initial and refined version of an MCED test that also provided a prediction of cancer signal origin (CSO). We sought to determine whether CSO prediction-guided diagnostic evaluations led to diagnostic resolution; whether participants with known risk factors for cancer beyond age alone and a negative initial diagnostic evaluation had a cancer diagnosis during study follow-up; the utility of whole body imaging (WBI) in reaching diagnostic resolution; and differences in the diagnostic journeys needed to reach diagnostic resolution for both true- and false-positive results. Of the 39 participants in this analysis, 82% (32/39) achieved diagnostic resolution after the initial evaluation, including 78% (25/32) who reached resolution specifically with a CSO prediction-directed workup. 18% (7/39) required additional evaluation for persistent clinical suspicion of cancer, all of whom achieved resolution (3 with and 4 without cancer). WBI contributed to diagnostic resolution in only 49% of cancer signal detected cases. Approximately 90% of true- and false-positive cases had imaging tests; more true- versus false-positives (81.0% vs 38.9%) had non-surgical and/or surgical procedures. In conclusion, CSO prediction-directed evaluations enabled diagnostic resolution for most participants, although some with negative initial evaluations but persistent suspicion of cancer required additional testing.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 years of follow-up in the Diabetes Prevention Program.","authors":"Brandy M Heckman-Stoddard, Jill P Crandall, Sharon L Edelstein, Philip C Prorok, Dana Dabelea, Richard Hamman, Helen P Hazuda, Edward Horton, Mary A Hoskin, Marjorie Perloff, Anna Bowers, William C Knowler, Leslie G Ford, Marinella Temprosa","doi":"10.1158/1940-6207.CAPR-23-0461","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-23-0461","url":null,"abstract":"<p><p>Meta-analyses have reported a decrease in overall cancer incidence of approximately 10-40% with metformin use among individuals with diabetes. Lifestyle change could potentially reduce cancer incidence. The objective was to determine whether metformin or intensive lifestyle intervention (ILS) reduces the risk of cancer among adults at high risk of diabetes. The Diabetes Prevention Program (DPP, 1996-2001) randomized 3234 participants to ILS, metformin (850 mg twice daily), or blinded placebo. During follow-up through the DPP Outcomes Study (DPPOS), all participants were offered a modified lifestyle intervention, and metformin continued open-label metformin group. Participants reported cancer cases annually. Medical records were adjudicated for all reported events. The primary endpoint was total cancer incidence, comparing metformin versus placebo, with ILS versus placebo as a secondary objective. After a median follow-up of 21 years, 546 participants (173 metformin, 182 ILS, and 191 placebo) were diagnosed with a first incident cancer. Incidence rates of cancer were 9.8, 10.5, and 10.8 per 1,000 person-years in metformin, ILS, and placebo, respectively, with a hazard ratio (HR) of 0.90 (95%CI = 0.73 to 1.10) for metformin compared to placebo and 0.96 (95%CI = 0.79 to 1.18) for ILS compared to placebo. There were no differences between any treatment groups for obesity-related cancer or in sex-specific analyses. Neither assignment to metformin nor ILS reduced cancer incidence among adults at high risk of diabetes. These results may be impacted by increased non-study metformin usage over time due to the development of diabetes and reduced intensity of ILS intervention over time.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From therapy to cancer prevention using HRD testing on high grade ovarian cancer patients.","authors":"Maria Grazia Tibiletti, Ileana Carnevali, Sofia Facchi, Valeria Pensotti, Giorgio Formenti, Nora Sahnane, Laura Libera, Susanna Ronchi, Sara Volorio, Marco Alessandro Pierotti, Stefano La Rosa, Fausto Sessa","doi":"10.1158/1940-6207.CAPR-24-0474","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-24-0474","url":null,"abstract":"<p><p>Approximately half of high-grade ovarian cancers are characterized by genetic and epigenetic alterations of genes involved in homologous recombination (HRR), most commonly BRCA1 and BRCA2. HRR defects identified by tests of genomic instability confer PARP-inhibitors sensitivity in ovarian cancers. Commercial tests that combine tumor BRCA testing with a genomic instability score (HRD test) are available in clinical practice. We seek to determine the performance of three different HRD tests to improve therapy management and prevention of ovarian cancer. Tumor samples from 50 patients with high grade ovarian cancers were investigated for tumoral BRCA status, genomic instability and BRCA1 promoter methylation for treatment purposes. Patients with ovarian cancer that tested positive for BRCA variants and/or genomic instability defect, were referred to the Cancer Genetics Service for germline testing. A positive HRD status was observed in 54% of cases and pathogenic variants of BRCA genes were identified in 41% of cases presenting genomic instability. BRCA1 methylation assay revealed promoter hypermethylation in 20% of ovarian cancers that tested positive for HRD and negative for BRCA1/2 variants. Among 26 women referred to cancer genetic counselling, 10 carried germline variants in HRR genes. HRD status determined eligibility for PARP inhibitor treatment in all but two ovarian cancers. This study outlined that determining genomic instability helps identify inherited ovarian cancers. HRD testing, crucial for making high-ovarian cancer treatment choices, must be linked to an established path of cancer genetic counselling and management of individuals at high cancer risk.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Loss Reverses the Effects of Aging and Obesity on Mammary Tumor Immunosuppression and Progression.","authors":"Laura A Smith, Dalton M Craven, Alyssa N Ho, Elaine M Glenny, Erika T Rezeli, Meredith S Carson, Evan M Paules, Magdalena Fay, Alyssa J Cozzo, Stephen D Hursting, Michael F Coleman","doi":"10.1158/1940-6207.CAPR-24-0514","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-24-0514","url":null,"abstract":"<p><p>Advanced age and obesity are each a major risk factor for breast cancer progression, including triple-negative breast cancer (TNBC). Here we interrogated: a) whether these factors interact to promote TNBC progression, and b) if weight loss mitigates the separate and combined effects of aging and obesity on TNBC. We demonstrate that aging and diet-induced obesity (DIO) interact to promote TNBC growth in mice. Transcriptomic analysis revealed suppression of antitumor immunity in tumors from aged and/or obese mice. Weight loss via intermittent calorie restriction (ICR) reduced tumor growth and restored immune-related gene signatures to reverse the protumor effects of aging and/or obesity. Using publicly available genomic datasets from murine studies of obesity, weight loss, and TNBC, we identified a consensus transcriptomic signature of obesity-driven immunosuppression that predicted survival of patients with breast cancer. This consensus signature was also suppressed by aging, obesity, and their combination. ICR reversed aging and/or obesity effects on the consensus signature. We conclude that aging and obesity interact to limit antitumor immunity and enhance TNBC progression and that these adverse effects can be disrupted by weight loss.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Incidence and Survival After Emergency Department Care in the U.S. Midwest: An Opportunity for Cancer Interception.","authors":"Mark E Sherman, Michael G Heckman, Christopher C DeStephano, Launia J White, Jennifer L St Sauver, Ruth M Pfeiffer","doi":"10.1158/1940-6207.CAPR-24-0426","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-24-0426","url":null,"abstract":"<p><p>Historically, cancers diagnosed via the Emergency Department (ED) portend a poor prognosis. Recent data from the United States (U.S.) are sparse and analyses of cancers detected in the years following ED visits are lacking. Thus, we analyzed data from 9 rural Midwest U.S. counties included within the population-based Rochester Epidemiology Project (REP) (2015-2021). Participants without a history of cancer (N=42,074) who did not receive ED care were matched 1:1 to ED participants on date of ED visit, age, sex, race, ethnicity and county of residence. Analyses were restricted to participants with records <2 years prior to ED or index visit and > 30 days after. Hazard ratios (HRs) and 95% confidence intervals (CIs) comparing cancer incidence and deaths among ED and non-ED participants were estimated from Cox proportional hazards regression models, either unadjusted or adjusted for covariates. Cumulative cancer incidence curves accounting for competing risks of death and survival (all cause and cancer-specific) were estimated. Median follow-up was 6.3 years, with 2719 (6.46%) cancers diagnosed among ED participants and 3139 (7.46%) among non-ED participants. ED participants experienced lower cancer risk overall (HRAdjusted=0.70, 95%CI: 0.66-0.74; p=8.89 X10-31), and specifically for breast cancer, prostate cancer, melanoma and secondary cancers. Cancer-specific mortality was higher among ED participants (HRAdjusted=1.76, 95%CI: 1.49-2.08; p=3.62X10-11). Compared with non-ED participants, ED participants experienced a lower incidence of cancer but higher overall cancer-specific mortality, suggesting that subsets of ED patients may benefit from post-visit preventive interventions.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Effects of High-Fiber and Low-Fiber Diets on Antitumor Immunity and Colon Tumor Progression in a Murine Model.","authors":"Kevin E Goggin, SeonYeong Jamie Seo, Benjamin G Wu, Sinisa Ivelja, Matthias C Kugler, Miao Chang, Fares Darawshy, Yonghua Li, Cecilia J Chung, Yaa Kyeremateng, Jun-Chieh J Tsay, Shivani Singh, Daniel H Sterman, Leopoldo N Segal, Nejat K Egilmez, Qingsheng Li","doi":"10.1158/1940-6207.CAPR-24-0159","DOIUrl":"10.1158/1940-6207.CAPR-24-0159","url":null,"abstract":"<p><p>The role of dietary fiber in colon cancer prevention remains controversial. We investigated its impact on antitumor immunity and the gut microbiota in APCmin/+ mice infected with enterotoxigenic Bacteroides fragilis. Mice were fed high-fiber, low-fiber, or chow diets, and the tumor burden, survival, cytokines, microbiota, and metabolites were analyzed. Contrary to the belief that high fiber inhibits tumor progression, it had no significant impact compared with chow diet. However, the low-fiber diet significantly reduced the tumor burden and improved survival. Mechanistically, high fiber increased proinflammatory cytokines and CD4+Foxp3+RORγt+IL-17A+ regulatory T cells, whereas low fiber enhanced anti-inflammatory cytokines and cytotoxic T cells. High fiber enriched microbial taxa associated with IL-17A+RORγt+ regulatory T cells and altered metabolites, including reduced tryptophan and increased short-chain fatty acids and bile acids. Low fiber produced opposite effects. These findings suggest that dietary fiber's effects on colon cancer depends on microbial infection and immune status, emphasizing the need for personalized dietary interventions in colon cancer management. Prevention Relevance: Dietary fiber's impact on colon cancer progression highlights the need for personalized dietary approaches, considering microbial infection and immune status.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"223-234"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editors' Selections from Relevant Scientific Publications.","authors":"","doi":"10.1158/1940-6207.CAPR-18-4-HFL","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-18-4-HFL","url":null,"abstract":"","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":"18 4","pages":"177"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reproductive and Hormonal Factors and Thyroid Cancer Risk: Pooled Analysis of Prospective Cohort Studies in the Asia Cohort Consortium.","authors":"Sayada Zartasha Kazmi, Aesun Shin, Sarah K Abe, Md Rashedul Islam, Md Shafiur Rahman, Eiko Saito, Sooyoung Cho, Ryoko Katagiri, Melissa A Merritt, Ji-Yeob Choi, Xiao-Ou Shu, Norie Sawada, Akiko Tamakoshi, Ritsu Sakata, Atsushi Hozawa, Seiki Kanemura, Jeongseon Kim, Yumi Sugawara, Sue K Park, Hui Cai, Shoichiro Tsugane, Takashi Kimura, Habibul Ahsan, Paolo Boffetta, Kee Seng Chia, Keitaro Matsuo, You-Lin Qiao, Nathaniel Rothman, Wei Zheng, Manami Inoue, Daehee Kang","doi":"10.1158/1940-6207.CAPR-24-0330","DOIUrl":"10.1158/1940-6207.CAPR-24-0330","url":null,"abstract":"<p><p>Given the female predominance of thyroid cancer, particularly in the reproductive age range, female sex hormones have been proposed as an etiology; however, previous epidemiological studies have shown conflicting results. We conducted a pooled analysis using individual data from nine prospective cohorts in the Asia Cohort Consortium to explore the association between 10 female reproductive and hormonal factors and thyroid cancer risk. Using Cox proportional hazards models, cohort-specific hazard ratios (HR) and 95% confidence intervals (CI) were estimated and then pooled using a random-effects model. Analyses were stratified by country, birth years, smoking status, and body mass index, and thyroid cancer risk based on age of diagnosis was also examined. Among 259,649 women followed up for a mean of 17.2 years, 1,353 incident thyroid cancer cases were identified, with 88% (n = 1,140) being papillary thyroid cancer. Older age at first delivery (≥26 vs. 21-25 years) was associated with increased thyroid cancer risk (P-trend = 0.003; HR = 1.16; 95% CI, 1.03-1.31), particularly when diagnosed later in life (≥55 vs. < 55 years; P-trend = 0.003; HR = 1.19; 95% CI, 1.02-1.39). Among younger birth cohorts, women with more number of deliveries showed an increased thyroid cancer risk [P-trend = 0.0001, HR = 2.40; 95% CI, 1.12-5.18 (≥5 vs. 1-2 children)], and there was no substantial trend in older cohorts. Distinct patterns were observed for the number of deliveries and thyroid cancer risk across countries, with a significant positive association for Korea [P-trend = 0.0008, HR = 1.89; 95% CI, 1.21-2.94 (≥5 vs. 1-2 children)] and nonsignificant inverse associations for China and Japan. Contextual and macrosocial changes in reproductive factors in Asian countries may influence thyroid cancer risk. Prevention Relevance: This analysis of prospective cohort studies across three Asian countries highlights that older age at first birth is linked to increased thyroid cancer risk. As women delay motherhood, understanding these trends is vital for public health strategies addressing reproductive factors influencing thyroid cancer risk in these populations.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"209-221"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Evaluation of an Automated Multimodal Mobile Detection of Oral Cancer Imaging System to Aid in Risk-Based Management of Oral Mucosal Lesions.","authors":"Ruchika Mitbander, David Brenes, Jackson B Coole, Alex Kortum, Imran S Vohra, Jennifer Carns, Richard A Schwarz, Ida Varghese, Safia Durab, Sean Anderson, Nancy E Bass, Ashlee D Clayton, Hawraa Badaoui, Loganayaki Anandasivam, Rachel A Giese, Ann M Gillenwater, Nadarajah Vigneswaran, Rebecca Richards-Kortum","doi":"10.1158/1940-6207.CAPR-24-0253","DOIUrl":"10.1158/1940-6207.CAPR-24-0253","url":null,"abstract":"<p><p>Oral cancer is a major global health problem. It is commonly diagnosed at an advanced stage, although often preceded by clinically visible oral mucosal lesions, termed oral potentially malignant disorders, which are associated with an increased risk of oral cancer development. There is an unmet clinical need for effective screening tools to assist front-line healthcare providers to determine which patients should be referred to an oral cancer specialist for evaluation. This study reports the development and evaluation of the mobile detection of oral cancer (mDOC) imaging system and an automated algorithm that generates a referral recommendation from mDOC images. mDOC is a smartphone-based autofluorescence and white light imaging tool that captures images of the oral cavity. Data were collected using mDOC from a total of 332 oral sites in a study of 29 healthy volunteers and 120 patients seeking care for an oral mucosal lesion. A multimodal image classification algorithm was developed to generate a recommendation of \"refer\" or \"do not refer\" from mDOC images using expert clinical referral decision as the ground truth label. A referral algorithm was developed using cross-validation methods on 80% of the dataset and then retrained and evaluated on a separate holdout test set. Referral decisions generated in the holdout test set had a sensitivity of 93.9% and a specificity of 79.3% with respect to expert clinical referral decisions. The mDOC system has the potential to be utilized in community physicians' and dentists' offices to help identify patients who need further evaluation by an oral cancer specialist. Prevention Relevance: Our research focuses on improving the early detection of oral precancers/cancers in primary dental care settings with a novel mobile platform that can be used by front-line providers to aid in assessing whether a patient has an oral mucosal condition that requires further follow-up with an oral cancer specialist.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"197-207"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}